|
Commercial Launch of Herceptin SC in EU Triggers Milestone Payment to …
Sacramento Bee In February 2011, Roche began a Phase 3 registration trial of subcutaneous (SC) MabThera (rituximab), an anticancer biologic, in patients with non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) and submitted a line extension … |
Scan Under the Radar for Promising BiotechsKapitall Blog (blog)Vice president of sales Michael Crum arrived in January after 13 years at Genentech (Roche Holding AG (RHHBY:OTCQX)), cross-trained in selling cancer treatments including Rituxan (rituximab…
|
Commercial Launch of Herceptin SC in EU Triggers Milestone Payment to …
PR Newswire (press release) In February 2011, Roche began a Phase 3 registration trial of subcutaneous (SC) MabThera (rituximab), an anticancer biologic, in patients with non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) and submitted a line extension … |
John McCamant Scans Under the Radar for Promising BiotechsInvestorIdeas.com (press release)Vice president of sales Michael Crum arrived in January after 13 years at Genentech ( Roche Holding AG (RHHBY:OTCQX)), cross-trained in selling cancer treatments…
Medscape |
Boxed warning for HBV risk added to Rituxan, Arzerra
Clinical Advisor The FDA has announced that the anti-CD20-directed monoclonal antibodies rituximab (Rituxan) and ofatumumab (Arzerra) will carry a boxed warning for immunosupression-related reactivation of hepatitis B virus (HBV) in a drug safety communication. Boxed Warning on HBV Reactivation for Blood Cancer DrugsMedscape FDA updates ‘box warning’ for Arzerra and Rituxan to include Hepatitis B …The Global Dispatch Boxed warning for potential HBV reactivation added to Arzerra, Rituxan labelingHealio Pharmaceutical Processing all 5 news articles » |
|
Boxed warning for potential HBV reactivation added to Arzerra, Rituxan labeling
Healio Rituxan (rituximab, Genentech) is a therapy for CLL, non-Hodgkin’s lymphoma and conditions that include microscopic polyangiitis, granulomatosis with polyangiitis and rheumatoid arthritis. These drugs, along with other CD20-directed cytolytic … |
MedscapeBoxed Warning on HBV Reactivation for Blood Cancer DrugsMedscapeA boxed warning about the risk for reactivation of hepatitis B virus (HBV) infection in patients who once had the virus has been added to the product labeling for 2 drugs used in t…
Application for Regulatory Approvals, Conferences and Presentations, and …PR Newswire (press release)According to Gilead, the data submitted for the NDA support the use of idelalisib for patients with iNHL that is refractory (non-responsive) to ritux…
Application for Regulatory Approvals, Conferences and Presentations, and …MarketWatch (press release)According to Gilead, the data submitted for the NDA support the use of idelalisib for patients with iNHL that is refractory (non-responsive) to ritux…
Boxed Warning of HBV Risk Added to Rituxan, ArezerraMedPage TodayThe FDA announced today that rituximab (Rituxan) and ofatumumab (Arzerra) will now carry a boxed warning of the risk for immunosuppression-related reactivation of hepatitis B virus (HBV)….